SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
41.35
+0.04 (+0.10%)
At close: 4:00PM EDT

41.35 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close41.31
Open41.17
Bid40.79 x 1000
Ask42.01 x 1200
Day's Range41.16 - 41.47
52 Week Range37.43 - 45.62
Volume582,645
Avg. Volume1,018,598
Market Cap101.843B
Beta (3Y Monthly)0.39
PE Ratio (TTM)21.31
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.86 (4.20%)
Ex-Dividend Date2018-05-09
1y Target Est52.00
Trade prices are not sourced from all markets
  • Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
    Zacks5 days ago

    Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

    Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

  • Sanofi Named One of America's Best Employers by Forbes
    PR Newswire5 days ago

    Sanofi Named One of America's Best Employers by Forbes

    BRIDGEWATER, N.J., April 17, 2019 /PRNewswire/ -- Forbes has named Sanofi one of America's Best Employers. This is the first time Sanofi has appeared on the Forbes list. "It is an amazing accomplishment when employees voice their pride and it leads to recognition," said Clint Wallace, Senior Vice President Human Resources, North America and Global Head of HR, Digital and Analytics.

  • Reuters5 days ago

    Boehringer's operating income flat as integration costs weigh

    German drugmaker Boehringer Ingelheim reported on Wednesday flat operating income of 3.5 billion euros ($4 billion) for 2018, held back by the costs of integrating the animal medicines business it acquired from Sanofi. Strong revenue gains from Boeringer's diabetes drugs were partly offset by declining revenues for its top-selling inhalable lung drug Spiriva, under pressure from rival drugs. As a result, total group sales fell 3 percent last year to 17.5 billion euros ($19.8 billion), the family-owned group said.

  • World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe
    PR Newswire5 days ago

    World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe

    BRIDGEWATER, N.J., April 17, 2019 /PRNewswire/ -- On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages. Hemophilia most often occurs in boys, and there is currently no cure.

  • Does Sanofi (EPA:SAN) Have A Good P/E Ratio?
    Simply Wall St.6 days ago

    Does Sanofi (EPA:SAN) Have A Good P/E Ratio?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to Sanofi's (EPA:SAN), to help you decide if the stock is worth further research...

  • CNW Group11 days ago

    Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)

    TORONTO , April 11, 2019 /CNW Telbec/ - Sanofi Genzyme, the Specialty Care Business Unit of sanofi-aventis Canda Inc, announced today that Health Canada has issued a Notice of Compliance with conditions (NOC/c) for LibtayoTM (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The market authorization is conditional pending the results of studies to verify its clinical benefit.

  • 3 Biotech Stocks That Doubled After Hitting Bottom in 2018
    Motley Fool12 days ago

    3 Biotech Stocks That Doubled After Hitting Bottom in 2018

    Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.

  • CNBC12 days ago

    Sanofi sets a fixed price of insulin at $99 per month for some patients

    The move is a pre-emptive one as the French drugmaker is set to testify before the House Energy and Commerce Committee on the rising prices of insulin later in the day.

  • Reuters13 days ago

    Sanofi to cut U.S. insulin costs for some patients to $99 per month

    Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. Sanofi announced the plan hours before one of its executives was set to testify before a congressional committee on the rising prices of insulin. Executives from the other leading insulin producers - Eli Lilly & Co and Novo Nordisk A/S - will also testify.

  • Sanofi provides unprecedented access to its insulins for one set monthly price
    PR Newswire13 days ago

    Sanofi provides unprecedented access to its insulins for one set monthly price

    BRIDGEWATER, N.J., April 10, 2019 /PRNewswire/ -- Starting in June, Sanofi will further expand its innovative Insulins Valyou Savings Program so people living with diabetes in the United States can pay $99 to access their Sanofi insulins* with a valid prescription, for up to 10 boxes of pens and/or 10 mL vials per month. "It is unacceptable to Sanofi that some people living with diabetes are struggling to pay for their insulin, so we have moved to act creatively and aggressively to help address affordability and access needs," said Michelle Carnahan, Head of North America Primary Care at Sanofi.

  • Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
    Zacks13 days ago

    Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

    Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

  • Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
    Zacks13 days ago

    Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

    Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

  • Alnylam trades partner Sanofi for Regeneron in $800M deal
    American City Business Journals14 days ago

    Alnylam trades partner Sanofi for Regeneron in $800M deal

    Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.

  • Inovio Closes Enrollment in Brain Cancer Study Before Time
    Zacks20 days ago

    Inovio Closes Enrollment in Brain Cancer Study Before Time

    Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

  • Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
    Zacks21 days ago

    Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

    Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

  • GlobeNewswire22 days ago

    Sanofi: Availability of the Pre-quarterly Results Communication

    As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group`s quarterly results. Sanofi`s first-quarter 2019 results will be published on April 26, 2019. Sanofi is dedicated to supporting people through their health challenges.

  • Benzinga24 days ago

    Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

    Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally ...

  • Benzinga24 days ago

    CDC: 44 States Still Reporting High Flu Activity

    At a time when the flu season is typically coming to a close, the Centers for Disease Control and Prevention said this week that the number of cases and related medical visits continue to be elevated. Flu season typically ranges from November to March, with flu-like illness peaking in February, the CDC said. The incidence of patients testing positive for the flu virus influenza A (H1N1), influenza A (H3N2) and influenza B are slightly increased for the most recent three-week period, with influenza A(H3) reported more frequently, according to the federal agency.

  • AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
    Zacks25 days ago

    AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

    AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

  • Lilly (LLY) Signs New Immunology Deal With Private Biotech
    Zacks26 days ago

    Lilly (LLY) Signs New Immunology Deal With Private Biotech

    Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

  • Sanofi (EPA:SAN): What We Can Expect From This Growth Stock
    Simply Wall St.26 days ago

    Sanofi (EPA:SAN): What We Can Expect From This Growth Stock

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Sanofi's (EPA:SAN) earnings update on 31 December 2018, analyst...

  • Were Hedge Funds Right About Selling Sanofi (SNY)?
    Insider Monkey27 days ago

    Were Hedge Funds Right About Selling Sanofi (SNY)?

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis
    Yahoo Finance Video10 days ago

    Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis

    "This opioid crisis has become a fentanyl crisis," the CEO of Opiant Dr. Roger Crystal told Yahoo Finance's Alexis Christoforous. He then goes on to discuss what else the pharmaceutical company is doing to tackle the epidemic.